GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Cyclically Adjusted PS Ratio

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Cyclically Adjusted PS Ratio : 2.93 (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Shenzhen Hepalink Pharmaceutical Group Co's current share price is HK$3.34. Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was HK$1.14. Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio for today is 2.93.

The historical rank and industry rank for Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

HKSE:09989' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.28   Med: 6.35   Max: 10.92
Current: 2.83

During the past years, Shenzhen Hepalink Pharmaceutical Group Co's highest Cyclically Adjusted PS Ratio was 10.92. The lowest was 2.28. And the median was 6.35.

HKSE:09989's Cyclically Adjusted PS Ratio is ranked worse than
62.85% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs HKSE:09989: 2.83

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Shenzhen Hepalink Pharmaceutical Group Co's adjusted revenue per share data for the three months ended in Mar. 2024 was HK$1.017. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is HK$1.14 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.18 6.84 6.22 4.12 3.51

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.35 3.58 3.74 3.51 2.44

Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio falls into.



Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.34/1.14
=2.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Shenzhen Hepalink Pharmaceutical Group Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.017/115.2271*115.2271
=1.017

Current CPI (Mar. 2024) = 115.2271.

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.594 98.200 0.697
201409 0.507 98.900 0.591
201412 0.513 99.000 0.597
201503 0.715 99.900 0.825
201506 0.434 99.500 0.503
201509 0.423 100.500 0.485
201512 0.639 100.600 0.732
201603 0.643 102.200 0.725
201606 0.493 101.400 0.560
201609 0.369 102.400 0.415
201612 0.569 102.600 0.639
201703 0.412 103.200 0.460
201706 0.550 103.100 0.615
201709 0.688 104.100 0.762
201712 0.925 104.500 1.020
201803 0.955 105.300 1.045
201806 1.203 104.900 1.321
201809 1.030 106.600 1.113
201812 1.350 106.500 1.461
201903 0.959 107.700 1.026
201906 1.006 107.700 1.076
201909 0.892 109.800 0.936
201912 1.326 111.200 1.374
202003 1.244 112.300 1.276
202006 1.103 110.400 1.151
202009 0.721 111.700 0.744
202012 1.391 111.500 1.437
202103 1.031 112.662 1.054
202106 1.520 111.769 1.567
202109 1.246 112.215 1.279
202112 1.447 113.108 1.474
202203 1.605 114.335 1.618
202206 1.477 114.558 1.486
202209 1.247 115.339 1.246
202212 1.340 115.116 1.341
202303 1.009 115.116 1.010
202306 1.054 114.558 1.060
202309 0.987 115.339 0.986
202312 1.030 114.781 1.034
202403 1.017 115.227 1.017

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Shenzhen Hepalink Pharmaceutical Group Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Executives
Orbimed Capital Llc 2102 Investment manager
Morgan Stanley & Co. International Plc 2105 Underwriter
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Avict Global Holdings Limited 2101 Beneficial owner
Worldwide Healthcare Trust Plc 2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines